Verastem/$VSTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Primary listing
Employees
102
Headquarters
Website
Verastem Metrics
BasicAdvanced
$480m
-
-$3.02
0.39
-
Price and volume
Market cap
$480m
Beta
0.39
52-week high
$11.25
52-week low
$4.01
Average daily volume
2.2m
Financial strength
Current ratio
3.091
Quick ratio
2.964
Long term debt to equity
142.193
Total debt to equity
152.401
Interest coverage (TTM)
-149.50%
Profitability
EBITDA (TTM)
-169.401
Gross margin (TTM)
85.12%
Net profit margin (TTM)
-677.59%
Operating margin (TTM)
-550.33%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-61.11%
Return on equity (TTM)
-1,480.15%
Valuation
Price to revenue (TTM)
12.241
Price to book
7.42
Price to tangible book (TTM)
10.41
Price to free cash flow (TTM)
-2.572
Free cash flow yield (TTM)
-38.88%
Free cash flow per share (TTM)
-2.123
Growth
Revenue change (TTM)
209.14%
Earnings per share change (TTM)
-17.42%
3-year revenue growth (CAGR)
128.36%
3-year earnings per share growth (CAGR)
-12.90%
10-year earnings per share growth (CAGR)
-16.93%
What the Analysts think about Verastem
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Verastem Financial Performance
Revenues and expenses
Verastem Earnings Performance
Company profitability
Verastem News
AllArticlesVideos
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Business Wire·22 hours ago
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Business Wire·1 week ago
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Verastem stock?
Verastem (VSTM) has a market cap of $480M as of May 01, 2026.
What is the P/E ratio for Verastem stock?
The price to earnings (P/E) ratio for Verastem (VSTM) stock is 0 as of May 01, 2026.
Does Verastem stock pay dividends?
No, Verastem (VSTM) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Verastem dividend payment date?
Verastem (VSTM) stock does not pay dividends to its shareholders.
What is the beta indicator for Verastem?
Verastem (VSTM) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.